Abstract
Australia has become the first country to approve the use of psychedelics, namely MDMA and psilocybin, for clinical treatment of post-traumatic stress disorder and treatment-resistant depression. Here, we briefly explore the history of its use, how it works, and the hope it may provide people receiving end-of-life care.
References
Therapeutic Goods Administration. Media Release: Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists [Internet]. 2023. Available from: https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists.
Schimmers N, Breeksema JJ, Smith-Apeldoorn SY, Veraart J, van den Brink W, Schoevers RA. Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review. Psychopharmacology. 2022;239(1):15-33.
Zafar R, Siegel M, Harding R, Barba T, Agnorelli C, Suseelan S, et al. Psychedelic therapy in the treatment of addiction: the past, present and future. Frontiers in Psychiatry. 2023;14:1183740.
Nardou R, Sawyer E, Song YJ, Wilkinson M, Padovan-Hernandez Y, De Deus JL, et al. Psychedelics reopen the social reward learning critical period. Nature. 2023;618(7966):790-798.
Lepow L, Morishita H, Yehuda R. Critical period plasticity as a framework for psychedelic-assisted psychotherapy. Frontiers in neuroscience. 2021;15:710004.
Strauss N, Bright SJ, Williams ML. Australia should be initiating a psychedelic research program: What are the barriers? : Sage Publications Sage UK: London, England; 2016. p. 1036-1037.
Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of±3, 4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of psychopharmacology. 2011;25(4):439-452.
Cahill M, Walker D, Gancarz A, Wang Z, Lardner C, Bagot R, et al. The dendritic spine morphogenic effects of repeated cocaine use occur through the regulation of serum response factor signaling. Molecular psychiatry. 2018;23(6):1474-1486.
Pilecki B, Luoma JB, Bathje GJ, Rhea J, Narloch VF. Ethical and legal issues in psychedelic harm reduction and integration therapy. Harm Reduction Journal. 2021;18(1):40.
Beck AT, Kovacs M, Weissman A. Hopelessness and suicidal behavior: An overview. Jama. 1975;234(11):1146-1149.
Fang C-K, Chang M-C, Chen P-J, Lin C-C, Chen G-S, Lin J, et al. A correlational study of suicidal ideation with psychological distress, depression, and demoralization in patients with cancer. Supportive Care in Cancer. 2014;22:3165-3174.
Vehling S, Kissane DW, Lo C, Glaesmer H, Hartung TJ, Rodin G, et al. The association of demoralization with mental disorders and suicidal ideation in patients with cancer. Cancer. 2017;123(17):3394-3401.
Chang T-G, Huang P-C, Hsu C-Y, Yen T-T. Demoralization in oral cancer inpatients and its association with spiritual needs, quality of life, and suicidal ideation: a cross-sectional study. Health and Quality of Life Outcomes. 2022;20(1):60.
Tecuta L, Tomba E, Grandi S, Fava GA. Demoralization: a systematic review on its clinical characterization. Psychological medicine. 2015;45(4):673-691.
WHO. ICD-11. International Classification of Diseases 11th Revision [Internet]. Available from: https://icd.who.int/en.
Figueiredo JMd. Distress, demoralization and psychopathology: Diagnostic boundaries. The European Journal of Psychiatry. 2013;27(1):61-73.
Clarke DM, Kissane DW. Demoralization: its phenomenology and importance. Australian & New Zealand Journal of Psychiatry. 2002;36(6):733-742.
Angelino AF, Treisman GJ. Major depression and demoralization in cancer patients: diagnostic and treatment considerations. Supportive Care in Cancer. 2001;9:344-349.
Mangelli L, Fava GA, Grandi S, Grassi L, Ottolini F, Porcelli P, et al. Assessing demoralization and depression in the setting of medical disease. Journal of clinical psychiatry. 2005;66(3):391-394.
Fava GA, Cosci F, Sonino N, Guidi J. Understanding health attitudes and behavior. The American journal of medicine. 2023;136(3):252-259.
Fava GA, Sonino N, Lucente M, Guidi J. Allostatic load in clinical practice. Clinical Psychological Science. 2023;11(2):345-356.
Fava GA, McEwen BS, Guidi J, Gostoli S, Offidani E, Sonino N. Clinical characterization of allostatic overload. Psychoneuroendocrinology. 2019;108:94-101.
Milstein JM. Introducing spirituality in medical care: transition from hopelessness to wholeness. Jama. 2008;299(20):2440-2441.
Breitbart W, Rosenfeld B, Gibson C, Pessin H, Poppito S, Nelson C, et al. Meaning‐centered group psychotherapy for patients with advanced cancer: a pilot randomized controlled trial. Psycho‐oncology. 2010;19(1):21-28.
Breitbart W, Rosenfeld B, Pessin H, Applebaum A, Kulikowski J, Lichtenthal WG. Meaning-centered group psychotherapy: an effective intervention for improving psychological well-being in patients with advanced cancer. Journal of clinical oncology. 2015;33(7):749-754.
Breitbart W, Pessin H, Rosenfeld B, Applebaum AJ, Lichtenthal WG, Li Y, et al. Individual meaning‐centered psychotherapy for the treatment of psychological and existential distress: A randomized controlled trial in patients with advanced cancer. Cancer. 2018;124(15):3231-3239.
Chochinov HM, Kristjanson LJ, Breitbart W, McClement S, Hack TF, Hassard T, et al. Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial. The lancet oncology. 2011;12(8):753-762.
Julião M, Oliveira F, Nunes B, Carneiro AV, Barbosa A. Effect of dignity therapy on end-of-life psychological distress in terminally ill Portuguese patients: a randomized controlled trial. Palliative & supportive care. 2017;15(6):628-637.
Garcia ACM, Schneiders M, da Mota KS, da Conceicao VM, Kissane DW. Demoralization and spirituality in oncology: an integrative systematic review. Supportive Care in Cancer. 2023;31(5):259.
Warth M, Kessler J, Koehler F, Aguilar-Raab C, Bardenheuer HJ, Ditzen B. Brief psychosocial interventions improve quality of life of patients receiving palliative care: A systematic review and meta-analysis. Palliative Medicine. 2019;33(3):332-345.
Anandarajah G, Roseman J, Mennillo LG, Kelley B. Spirituality in primary palliative care and beyond: A 20-year longitudinal qualitative study of interacting factors impacting physicians’ spiritual care provision over time. Journal of Pain and Symptom Management. 2021;62(6):1216-1228.
Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of psychopharmacology. 2016;30(12):1165-1180.
Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Ponté KL, Guss J, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of psychopharmacology. 2020;34(2):155-166.
Chrysanthos N. It’s going to be for people with money’: Psychedelic treatments tipped to cost at least $25,000 [Internet]. Sydney, Australia: The Sydney Morning Herald; 2023. Available from: https://www.smh.com.au/politics/federal/it-s-going-to-be-for-people-with-money-psychedelic-treatments-tipped-to-cost-at-least-25-000-at-first-20230313-p5crpd.html.
Marseille E, Stauffer CS, Agrawal M. Group psychedelic therapy: empirical estimates of cost-savings and improved access. Frontiers in Psychiatry. 2023;14:1293243.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Jennifer A. Ong (Author)